Table 1. Patient demographics and disease characteristics.
| Characteristic | Evaluable patientsa (N = 16) |
|---|---|
| Median age at baseline, years (range) | 34.9 (20.5–49.4) |
| Median age at time of treatment discontinuation, years (range) | 38.2 (25.1–52.1) |
| Sex, n (%) | |
| Male | 8 (50.0) |
| Female | 8 (50.0) |
| Race, n (%) | |
| Caucasian | 14 (87.5) |
| Asian | 2 (12.5) |
| WHO performance status at baseline, n (%) | |
| 0 | 11 (68.8) |
| 1 | 4 (25.0) |
| 2 | 1 (6.3) |
| Median body mass index at baseline, kg/m2 (range) | 24.25 (19.8–29.0) |
| Median body surface area at baseline, m2 (range) | 1.83 (1.62–2.14) |
| Sum of volumes of target renal angiomyolipoma lesions, cm3 | |
| Mean (standard deviation) | 248.72 (254.9) |
| Median (range) | 154.67 (24.1–861.4) |
aPatients with at least one valid efficacy assessment during the non-interventional follow-up phase.